3.280PLN+11.95%Mkt Cap: 9.09M $P/E: —11d ago
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap9.09M $
Enterprise Value13.13M $
Revenue (TTM)—
Gross Profit-7.34K $
Net Income (TTM)-2.49M $
Revenue/Share—
Last Price3.280 PLN
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLPRBLG00010
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-7.95
EV/Revenue—
P/S—
P/B-2.19
EPS (TTM)-1.68
EPS (Forward)—
52W Range
1.35325% of range9.200
52W High9.200 PLN
52W Low1.353 PLN
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE69.41%
ROA-198.79%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.58M $
CapEx (TTM)—
FCF Margin—
FCF Yield-11.60%
Net Debt3.91M $
Net Debt/EBITDA-2.36
Balance Sheet
Debt/Equity-1.13
Current Ratio0.09
Quick Ratio0.08
Book Value/Sh-1.3390 PLN
Cash/Share0.0830 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 PLN
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.12.24M
Float10.70M
Insiders1.38%
Institutions0.03%
Technical
SMA 502.317 (+41.6%)
SMA 2003.089 (+6.2%)
Beta0.21
S&P 52W Chg19.79%
Avg Vol (30d)368.75K
Avg Vol (10d)572.82K
Technical Indicators
RSI (14)70.2
MACD0.1269
MACD Signal0.0561
MACD Hist.+0.0708
BB Upper3.014 PLN
BB Middle2.418 PLN
BB Lower1.822 PLN
BB Width49.32%
ATR (14)0.3143 PLN
Vol Ratio (20d)2.63x